v3.26.1

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2026	Dec. 31, 2025
Current assets:
Cash	$ 63,614	$ 88,857
Restricted cash	20,000	20,000
Accounts receivable	2,058	51,324
Prepaid & other current assets	1,979,377	1,038,071
Total current assets	2,065,049	1,198,252
In process R&D	1,101,760	1,101,760
Goodwill, net of impairment	2,788,230	2,788,230
Investment in GMP Bio at fair value	388,000,000	388,000,000
Total assets	393,955,039	393,088,242
Current liabilities:
Accounts payable and accrued liabilities	2,470,889	2,571,123
Contingent consideration	2,625,000	2,625,000
Derivative liability on notes	440,124	350,044
Total current liabilities	18,403,989	18,143,278
Convertible long-term debt, net of costs	1,789,509	1,663,405
Deferred income tax liability	111,550,000	111,550,000
Total liabilities	131,743,498	131,356,683
Commitments and contingencies (Note 13)
Stockholders’ equity:
Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized; 50,900 and 24,388 shares issued and outstanding, respectively	509	244
Common stock, $0.01 par value; 750,000,000 shares authorized; 444,197,302 and 442,596,856 issued and outstanding, respectively	4,441,970	4,425,968
Additional paid-in capital	49,798,210	47,095,219
Accumulated equity	209,045,388	211,239,164
Total Oncotelic Therapeutics, Inc. stockholders’ equity	263,286,077	262,760,595
Non-controlling interests	(1,074,536)	(1,029,036)
Total stockholders’ equity	262,211,541	261,731,559
Total liabilities and stockholders’ equity	393,955,039	393,088,242
Related Party [Member]
Current liabilities:
Accounts payable to related party	348,625	348,111
Convertible debt and short-term debt, net of costs	4,273,152	4,023,331
Nonrelated Party [Member]
Current liabilities:
Convertible debt and short-term debt, net of costs	$ 8,246,199	$ 8,225,669

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

Oncotelic Therapeutics, Inc. 10-Q